M.R. Adams*, G.J. Blake, S. Kinlay, A.P. Selwyn, J.J. Popma.

The Department of Cardiology, Brigham and Women's Hospital, Boston MA, U.S.A.

Vascular closure devices offer potential advantages over traditional means of obtaining vascular haemostasis after percutaneous coronary interventions (PCI). The vascular complication rate, however, is not known in patients who undergo Angioseal deployment with concurrent glycoprotein IIb/IIIa (GP 2b/3a) receptor blockade for high risk coronary interventions. We aimed to determine the vascular complication rates in patients who underwent Angioseal deployment following PCI with and without GP2b/3a receptor blockade.

Over the 12-month period there were 1,785 PCIs performed. Vascular closure devices were used in 820 of these patients (750 Angioseal, 70 Vasoseal and Perclose devices). Retrospective analysis of 750 consecutive patients in whom Angioseal was deployed over a 12-month period at our institution was conducted. The patients were divided into 2 groups, those who did not receive GP2b/3a receptor blockade (Group 1) and those who did (Group 2). The vascular complication rates for each group were analysed.

There was no difference in the overall vascular complication rate (3.0% in group 1 vs 4.8% in group 2, p=0.2). There was a non-significant trend towards increased haematoma formation with GP2b/3a receptor blockade use. The results are summarised in the table below.

Angioseal deployment to achieve vascular haemostasis is a reasonable strategy in selected patients receiving GP2b/3a receptor blockade during PCI.

[ Back to 48th ASM Abstract Index ]